Amoxapine

Depression, Generalized Anxiety Disorder, Agitation + 4 more
Treatment
20 Active Studies for Amoxapine

What is Amoxapine

AmoxapineThe Generic name of this drug
Treatment SummaryAmoxapine is a type of antidepressant called a tricyclic antidepressant (TCA). It is related to the antipsychotic drug loxapine and works to increase serotonin and norepinephrine levels in the brain. This can help improve mood in people with depression. Amoxapine is used to treat depression, anxiety, and mixed symptoms of depression and anxiety. Common side effects of TCAs include sedation, low blood pressure, blurred vision, dry mouth, constipation, and urinary retention.
Amoxapineis the brand name
image of different drug pills on a surface
Amoxapine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Amoxapine
Amoxapine
1992
5

Effectiveness

How Amoxapine Affects PatientsAmoxapine is a type of antidepressant that is known to have a calming effect. It works differently than other antidepressants and has been shown to reduce the uptake of certain chemicals in the brain (nor-epinephirine and serotonin) and block the response of dopamine receptors to dopamine. It does not work as a monoamine oxidase inhibitor. Clinical studies have shown that amoxapine starts working faster than other antidepressants, such as amitriptyline and imipramine.
How Amoxapine works in the bodyAmoxapine works by preventing the body from reabsorbing the chemical messengers norepinephrine and serotonin.

When to interrupt dosage

The suggested dosage of Amoxapine is subject to the determined illness, for instance Neurotic depression, Psychotic Depression and Agitation. The amount of dosage depends on the method of delivery (e.g. Oral or Tablet) featured in the table beneath.
Condition
Dosage
Administration
Agitation
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Depression
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Generalized Anxiety Disorder
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Mental Depression
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Psychotic Depression
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Mental Depression
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral
Neurotic depression
, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg
, Oral, Tablet, Tablet - Oral

Warnings

Amoxapine Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Amoxapine.
Common Amoxapine Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Amoxapine is combined with Aclidinium.
Alfuzosin
Major
Amoxapine may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Amoxapine may increase the antipsychotic activities of Amisulpride.
Aripiprazole
Major
Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Amoxapine Toxicity & Overdose RiskTaking too much amoxapine can have serious side effects, such as seizures, coma, abnormal acid levels in the body, and kidney failure. Seizures are the most common symptom, and can lead to a medical emergency called status epilepticus. In rare cases, kidney failure can develop a couple days after overdosing.
image of a doctor in a lab doing drug, clinical research

Amoxapine Novel Uses: Which Conditions Have a Clinical Trial Featuring Amoxapine?

819 active clinical trials are investigating the potential of Amoxapine in treating Neurotic Depression, Agitation and Mental Despondency.
Condition
Clinical Trials
Trial Phases
Psychotic Depression
0 Actively Recruiting
Generalized Anxiety Disorder
178 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3
Mental Depression
0 Actively Recruiting
Mental Depression
0 Actively Recruiting
Neurotic depression
0 Actively Recruiting
Depression
300 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Agitation
3 Actively Recruiting
Phase 2, Phase 3, Not Applicable

Amoxapine Reviews: What are patients saying about Amoxapine?

5Patient Review
9/13/2020
Amoxapine for Depression
This drug was more effective than similar treatments I've tried in the past. At first, I experienced periods of involuntary yawning, but I quickly got used to it. My concentration while on this medication was amazing.
5Patient Review
12/8/2008
Amoxapine for Depression
5Patient Review
8/3/2011
Amoxapine for Depression
Amoxapine has been a complete game-changer for me since I started taking it in 1981.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about amoxapine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the brand name for amoxapine?

"Amoxapine is a tricyclic antidepressant that is used to treat symptoms associated with depression, anxiety, or agitation."

Answered by AI

What is amoxapine used to treat?

"This medicine is used to treat the symptoms of depression by increasing levels of certain chemicals in the brain. This medicine is a tricyclic antidepressant (TCA) and is available only with a doctor's prescription."

Answered by AI

Is amoxapine an antipsychotic?

"The drug Amoxapine is marketed as an antidepressant, though it has similar in-vitro profiles, receptor occupancies, and preclinical effects to atypical antipsychotics. Amoxapine has shown to be effective as an atypical antipsychotic in open trials."

Answered by AI

What are the side effects of amoxapine?

"popular antidepressants can cause a number of

side effects, including nausea, drowsiness, weakness or tiredness, nightmares, dry mouth, skin more sensitive to sunlight than usual, changes in appetite or weight, and constipation."

Answered by AI

Clinical Trials for Amoxapine

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Amoxapine clinical trials? We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Amoxapine clinical trials? We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.Go to Trials
Image of Caron Treatment Centers in Wernersville, United States.

Safe and Sound Protocol for Substance Abuse

18 - 75
All Sexes
Wernersville, PA
This study will explore whether the use of the Safe and Sound Protocol (SSP) app is an effective adjunct to treatment as usual (TAU) in individuals with co-occurring substance use disorders and trauma. This study will recruit 129 participants (100 completers) randomized to receive either active or sham SSP in addition to TAU. Participants will utilize the SSP for a minimum of three hours to a maximum of five hours for a total of seven days. Data will be collected at both pre- and post-test. Data to be collected will include measures on affect, anxiety, personality, mindfulness, and posttraumatic stress disorder symptoms. The SSP has shown effectiveness in reducing symptoms of anxiety, depression, and trauma symptoms in pilot studies conducted at other locations. This will be the first study to examine the effectiveness of SSP with individuals with co-occurring SUD and trauma.
Waitlist Available
Device
Caron Treatment CentersErin Deneke, PhD
Image of Cresap Laboratory in Evanston, United States.

Dream Yoga Inspired Intervention for Anxiety

18+
All Sexes
Evanston, IL
This is a feasibility study to test whether it is possible to deliver a program inspired by Tibetan Dream Yoga in a modern, accessible way. Dream Yoga is a set of contemplative practices that combine mental exercises during the day with techniques for becoming aware of dreaming within a dream (lucid dreaming) and engage in certain dream activities. The purpose of these practices is to help people explore and loosen rigid patterns of thought and behavior. In this study, the investigators are developing and testing a program that includes guided imagination, meditation, and lucid-dreaming practices, supported by virtual-reality experiences and home-based sleep-monitoring technology. Participants are randomly assigned to either the Dream-Yoga-inspired program or a comparison program focused on general health and sleep education. Because this is a feasibility trial, our main goals are to see whether people are willing and able to take part, whether they find the program acceptable, and whether the investigators can deliver it as planned. The investigators will also explore early signals of change in sleep, dreaming, and thinking. The long-term goal of this research is to determine if such interventions could be beneficial for supporting psychological well-being, improving sleep, and enhancing creativity and flexibility of thought.
Phase < 1
Waitlist Available
Cresap Laboratory (+1 Sites)
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Waitlist Available
Has No Placebo
Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth CollegeJames Sargent, MD
Have you considered Amoxapine clinical trials? We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security